Vera Therapeutics, Inc. (VERA) stock
VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.20−0.77 (-2.86%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Vera Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vera Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$338.65M. For fiscal 2025 it was -$241.10M. The highest annual figure on record is -$23.71M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$241.10M | – |
| FY2024 | Dec 31, 2024 | -$134.68M | – |
| FY2023 | Dec 31, 2023 | -$92.18M | – |
| FY2022 | Dec 31, 2022 | -$67.60M | – |
| FY2021 | Dec 31, 2021 | -$23.71M | – |
| FY2020 | Dec 31, 2020 | -$34.81M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$100.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$106.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$69.99M | – |
| Q3 FY2025 | Sep 30, 2025 | -$61.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$54.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$36.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.78M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.77M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.03M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.48M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.67M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.12M | – |
| Q4 FY2020 | Dec 31, 2020 | -$27.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.68M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.31M | – |
See a number that looks wrong?